| CEO Name | Heather Bresch |
| Nationality | United States |
| Net Worth Estimation | $30 million |
Heather Bresch's estimated net worth of around $30 million primarily stems from her long executive tenure at Mylan N.V., where she received substantial compensation packages, stock options, and bonuses. Her wealth is also augmented by investments and roles on corporate boards related to the healthcare and pharmaceutical sectors.
Heather Bresch's estimated net worth of $30 million places her in the top 4.1% of pharmaceutical CEOs based on a net worth range of $10 million to $500 million. She holds a mid-to-upper tier position relative to her industry peers.
Business Category: Pharmaceutical
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 500000000 USD
Heather Bresch Performance in Mylan N.V.
Heather Bresch, former CEO of Mylan N.V., demonstrated strategic leadership by driving global expansion and navigating complex regulatory environments. Her decision-making emphasized aggressive market growth, most notably in generic pharmaceuticals and the EpiPen product line, though it faced controversy over pricing practices. Bresch's tenure significantly increased Mylan's revenue and market presence but also resulted in legal and reputational challenges influencing the company's long-term performance.
Latest News
Mylan N.V. and Its CEO in Spotlight for Opioid Settlement and Pricing Controversies
Mylan N.V., now part of Viatris, has agreed to pay up to $335 million in a multistate settlement for its role in fueling the opioid crisis by allegedly deceptively marketing opioids as less prone to abuse, while its former CEO Heather Bresch faced intense criticism for EpiPen price hikes and was accused of conspiring to maintain a monopoly on the life-saving device. Both the company and its leadership have drawn scrutiny from lawmakers and the public for business practices prioritizing profits over patient welfare.
Source: http://ag.ny.gov/press-release/2025/attorney-general-james-secures-335-million-pharmaceutical-company-mylan-its-role